Latest Investments News

Virgin Australia reported a 3% revenue increase and a 28% rise in underlying EBIT for FY25, while statutory net profit fell 12% due to IPO and Qatar Airways transaction costs. The airline expanded its fleet and loyalty program amid ongoing transformation efforts.

Novatti Group Limited reported a 24.1% revenue increase to $50.48 million for FY2025 alongside a 69.7% reduction in losses. However, the company’s balance sheet weakness and ongoing audit spotlight raise questions about its financial sustainability.

Mesoblast Limited marked a transformative year with FDA approval and commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, driving a 191% jump in cell therapy revenues. The company is now poised to expand its footprint in inflammatory diseases with multiple clinical trials and label extensions underway.

Bapcor Limited reported a modest revenue decline and an 8.4% drop in pro-forma NPAT for FY25 amid significant business simplification and strategic initiatives aimed at sustainable growth.

PainChek Limited reported a 24% revenue increase to $4.8 million for FY25, narrowing its net loss by 7%, while progressing toward FDA clearance for its Adult PainChek App in the US and launching its Infant App in Australia.

Mesoblast reports a strong FY2025 financial performance driven by the commercial launch of Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in children. The company is advancing multiple clinical programs targeting inflammatory diseases, heart failure, and chronic low back pain.

Scalare Partners reports a 26% rise in FY25 revenue, driven by strong service demand and key acquisitions, including Inhouse Ventures and the pending Tank Stream Labs deal.

Xamble Group Limited reported a sharp 39% revenue decline and a doubling of losses in H1 FY2025, driven by strategic exit from Taiwan and increased technology spending. Despite financial setbacks, operational metrics show strong user and client growth, underpinning the company’s Southeast Asia-focused transformation.

Scalare Partners Holdings Limited reported a 26% increase in total revenues to $3.54 million for FY25, driven by strong growth in founder support services and strategic acquisitions. However, the Group recorded a statutory loss of $2.65 million amid increased structural and compliance costs following its ASX listing and expansion.

Bapcor Limited reported a 117% jump in statutory net profit after tax for FY25, driven by lower significant items despite a slight revenue decline. The company’s strategic reset, including store consolidations and IT upgrades, sets the stage for renewed growth.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.

NobleOak Life Limited reported robust FY25 results, with a 20% increase in in-force premiums and a 22% rise in underlying NPAT, underpinned by strategic investments in AI and a transition to a capital-efficient Life Company structure.